{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:09:55Z","timestamp":1785427795804,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.rmed.2024.107919","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:42:38Z","timestamp":1734828158000},"page":"107919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The minimally important difference in the six-minute walk test predicts clinical worsening in pulmonary arterial hypertension"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-4996","authenticated-orcid":false,"given":"Arsal","family":"Tharwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Minai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5862-0299","authenticated-orcid":false,"given":"Youlan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-2599","authenticated-orcid":false,"given":"Gustavo A.","family":"Heresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2024.107919_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Contr. Clin. Trials"},{"issue":"3","key":"10.1016\/j.rmed.2024.107919_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2024.107919_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1513\/pats.200803-029SK","article-title":"Surrogate and combined end points in pulmonary arterial hypertension","volume":"5","author":"Ventetuolo","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"13","key":"10.1016\/j.rmed.2024.107919_bib5","article-title":"Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension","volume":"60","author":"Savarese","year":"2012"},{"issue":"2","key":"10.1016\/j.rmed.2024.107919_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1378\/chest.12-0270","article-title":"Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension","volume":"143","author":"Fritz","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2024.107919_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2024.107919_bib10","first-page":"1119","volume":"vol. 358","author":"Channick","year":"2001"},{"issue":"20","key":"10.1016\/j.rmed.2024.107919_bib11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2024.107919_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2024.107919_bib15","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1164\/rccm.202208-1547OC","article-title":"Minimal clinically important difference in the six-minute walk distance for patients with pulmonary arterial hypertension","volume":"207","author":"Moutchia","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"22","key":"10.1016\/j.rmed.2024.107919_bib16","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.rmed.2024.107919_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.rmed.2024.107919_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/2045894021995055","article-title":"A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension","volume":"11","author":"Bunclark","year":"2021","journal-title":"Pulm. Circ."},{"issue":"1 SUPPL. 1","key":"10.1016\/j.rmed.2024.107919_bib19","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.rmed.2024.107919_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2024.107919_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"20","key":"10.1016\/j.rmed.2024.107919_bib22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Barst","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2024.107919_bib23","first-page":"265","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension","author":"Casserly","year":"2008","journal-title":"Drug Des. Dev. Ther."},{"issue":"12","key":"10.1016\/j.rmed.2024.107919_bib24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2024.107919_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil , a prostacyclin analogue, in patients with pulmonary arterial hypertension","volume":"165","author":"Simonneau","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2024.107919_bib26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.healun.2014.02.019","article-title":"Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"33","author":"Simonneau","year":"2014","journal-title":"J. Heart Lung Transplant."},{"issue":"16","key":"10.1016\/j.rmed.2024.107919_bib27","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Meyer","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000370124","article-title":"Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension","volume":"89","author":"Huang","year":"2015","journal-title":"Respiration"},{"issue":"5","key":"10.1016\/j.rmed.2024.107919_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.12-3023","article-title":"Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis","volume":"144","author":"Frost","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2024.107919_bib30","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2017.12.010","article-title":"Pulmonary arterial hypertension-related morbidity is prognostic for mortality","volume":"71","author":"McLaughlin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.rmed.2024.107919_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00190-2023","article-title":"Early View Heterogeneity of treatment effects by risk in pulmonary arterial hypertension","volume":"62","author":"Pan","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2024.107919_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1183\/09031936.00092311","article-title":"The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension","volume":"39","author":"Nickel","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"23","key":"10.1016\/j.rmed.2024.107919_bib33","first-page":"1","article-title":"Articles Is low-risk status a surrogate outcome in pulmonary arterial hypertension ? An analysis of three randomised trials","volume":"2600","author":"Blette","year":"2023","journal-title":"Lancet Respir"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T17:21:02Z","timestamp":1738603262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124003949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S0954611124003949"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107919","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The minimally important difference in the six-minute walk test predicts clinical worsening in pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107919"}}